- 1 Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection
- 2 in protecting against SARS-CoV-2 infections during the Delta and Omicron
- 3 variant waves; the UK SIREN cohort study September 2021 to February 2022
- 4 Corresponding author:
- 5 Victoria J Hall, victoria.hall@ukhsa.gov.uk, 01842 768 282
- 6 Postal address: SIREN Team, UK Health Security Agency, Nobel House, 17 Smith
- 7 Square, London, SW1P 3JR
- 8
- 9 Authors (*contributed equally and share first authorship)
- 10 Victoria J Hall*¹ <u>victoria.hall@ukhsa.gov.uk</u> ORCID 0000-0001-8744-4277
- 11 Ferdinando Insalata*^{1,2} <u>ferdinando.insalata@ukhsa.gov.uk</u>
- 12 Sarah Foulkes^{*1} <u>sarah.foulkes@ukhsa.gov.uk</u> ORCID 0000-0001-7241-6345
- 13 Peter Kirwan ^{1,3} peter.kirwan@mrc-bsu.cam.ac.uk ORCID 0000-0001-6904-0500
- 14 Dominic Sparkes¹ <u>dominic.sparkes@ukhsa.gov.uk</u>
- 15 Ana Atti¹ ana.atti@ukhsa.gov.uk
- 16 Michelle Cole¹ <u>michelle.cole@ukhsa.gov.uk</u>
- 17 Elen de Lacy⁴ <u>elen.delacy@wales.nhs.uk</u>
- 18 Lesley Price^{5,6} <u>I.price@gcu.ac.uk</u>
- 19 Diane Corrigan⁷ <u>Diane.Corrigan@hscni.net</u>
- 20 Colin S Brown¹ <u>colin.brown@ukhsa.gov.uk</u>
- 21 Jasmin Islam¹ jamin.islam@ukhsa.gov.uk
- 22 The SIREN Study Group
- 23 Andre Charlett¹ <u>andre.charlett@ukhsa.gov.uk</u>
- 24 Susan Hopkins¹ <u>susan.hopkins@ukhsa.gov.uk</u>
- 25
- 26 Affiliations
- UK Health Security Agency, UK Health Security Agency, Nobel House, 17
 Smith Square, London, SW1P 3JR
- Department of Mathematics, Imperial College London, London, SW7 2AZ,
 United Kingdom
- 3. MRC Biostatistics Unit, University of Cambridge, Institute of Public Health.
- 32 Forvie Site. Robinson Way. Cambridge. CB2 0SR
- 4. Public Health Wales, 2 Capital Quarter Tyndall Street Cardiff CF10 4BZ
- 34 5. Glasgow Caledonian University, Cowcaddens Road, Glasgow G4 0BA

- Public Health Scotland, Gyle Square 1 South Gyle Crescent, Edinburgh EH12
 9EB
- Public Health Agency Northern Ireland, Unit 12-22 Linenhall Street, Belfast
 BT2 8BS
- 39
- 40

41 **ABSTRACT**

Third doses of COVID-19 vaccines were widely deployed following primary vaccine course waning and emergence of the Omicron-variant. We investigated protection from third-dose vaccines and previous infection against SARS-CoV-2 infection during Delta-variant and Omicron-variant (BA.1 & BA.2) waves in our frequently PCR-tested cohort of healthcare-workers.

47

Relative effectiveness of BNT162b2 third doses and infection-acquired immunity was assessed by comparing the time to PCR-confirmed infection in boosted participants with those with waned dose-2 protection (≥254 days after dose-2). Follow-up time was divided by dominant circulating variant: Delta 07 September 2021 to 30 November 2021, Omicron 13 December 2021 to 28 February 2022. We used a Cox regression model with adjustment/stratification for demographic characteristics and staff-type. We explored protection associated with vaccination, infection and both.

We included 19,614 participants, 29% previously infected. There were 278 primary 55 infections (4 per 10,000 person-days of follow-up) and 85 reinfections (0.8/10,000 56 57 person-days) during the Delta period and 2467 primary infections (43/10,000 persondays) and 881 reinfections (33/10,000) during the Omicron period. Relative Vaccine 58 Effectiveness (VE) 0-2 months post-3rd dose (V3) (3-doses BNT162b2) in the 59 previously uninfected cohort against Delta infections was 63% (95% Confidence 60 Interval (CI) 40%-77%) and was lower (35%) against Omicron infection (95% CI 61 62 21%-47%). For primary course ChAdOX1 recipients, BNT162b2 heterologous third doses were especially effective, with VE 0-2 months post-V3 over ≥68% higher for 63 64 both variants. Third-dose protection waned rapidly against Omicron, with no 65 significant difference between two and three BNT162b2 doses observed after 4-Previous infection continued to provide additional protection against 66 months. 67 Omicron (67% (CI 56%-75%) 3-6 months post-infection), but this waned to about 25% after 9-months, approximately three times lower than against Delta. 68

Infection rates surged with Omicron emergence. Third doses of BNT162b2 vaccine
 provided short-term protection, with rapid waning against Omicron infections.
 Protection associated with infections incurred before Omicron was markedly
 diminished against the Omicron wave. Our findings demonstrate the complexity of

- an evolving pandemic with potential emergence of immune-escape variants and the
- ⁷⁴ importance of continued monitoring.

75

76

77

78 BACKGROUND

79 Third doses of COVID-19 vaccines (V3) were widely deployed in winter 2021/2022 in 80 the United Kingdom (UK) and other high-income countries (source our world in data). Third doses were first deployed in the Autumn 2021 (Delta-variant dominant period), 81 targeted in the UK to those considered at higher risk of severe disease (older age, 82 immunosuppressed) and to those providing healthcare to these individuals,¹ in 83 84 response to mounting evidence of waning vaccine effectiveness against symptomatic illness,²⁻⁵ and infection,⁶⁻⁸ six months after administration of the second 85 dose. Neutralising antibody titres, associated with vaccine efficacy, were shown to 86 be greatly increased by a booster vaccination.⁹⁻¹² 87

In late November 2021, with the rapid emergence and rapid spread of the Omicron variant, access to third doses was widened to all those over the age of 18 years as a response measure in the UK.¹³ With over five-fold more mutations in the Spike and Receptor Binding Domain (RBD) proteins compared to the Delta-variant, higher rates of evasion from both vaccine- and infection-acquired immunity were anticipated.^{14,15}

The SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) study, a large prospective cohort study of UK healthcare workers undergoing fortnightly PCR screening, has tracked primary infections and reinfections continuously since June 2020. Conducting daily monitoring to identify reinfections and vaccine breakthroughs, Omicron was rapidly identified as a step-change in our cohort, with rates of reinfections rapidly rising in the cohort, despite vaccination.

In this analysis we investigate the effectiveness of third doses with BNT162b2
 vaccines, including the impact of hybrid-immunity against SARS-CoV-2 infection in
 our frequently PCR-tested cohort of healthcare-workers.

102

103

104 **METHODS**

105 Study Design and Oversight

The SIREN study is an ongoing, multicentre, prospective cohort study involving
 health care workers (≥18 years of age) in the United Kingdom (ISRCTN

108 11041050)¹⁶. All the authors vouch for the accuracy and completeness of the data
and for the fidelity of the study to the protocol.

110

111 **Participant Involvement**

112 At its core the SIREN study is a collaboration between participants and researchers. 113 We are committed to ensuring participant feedback is heard, respected, and 114 influences our research. The SIREN study runs a comprehensive engagement programme providing participants with regular opportunities to engage with, and 115 116 feedback on, our research. The SIREN Participant Involvement Panel (PIP) is central 117 to this, providing timely ongoing participant input into cohort recruitment and 118 retention, study developments and communications. PIP members represent the 119 diversity of the SIREN cohort and are supported by experts in participant 120 engagement research.

121

122 Study Participants and Data

Participants underwent PCR testing for SARS-CoV-2 every two weeks, 123 124 supplemented by widespread lateral-flow testing, and regular (monthly or guarterly) 125 antibody testing. Data sources have been described previously.⁶ Participants were 126 included in this analysis if they had received at least two doses of COVID-19 vaccine 127 and their previous infection status at the point of entry to the analysis period was 128 known. Participants were excluded if the outcome could not be determined (e.g., if 129 they did not undergo PCR testing during the follow-up period), or if the date of onset 130 of the primary infection, based on either a positive PCR test or COVID-19 symptoms, 131 was not available. We included participants whose primary vaccine course was 132 either BNT162b2 vaccine (Pfizer-BioNTech) or ChAdOx1 nCoV-19 vaccine (AstraZeneca), and whose booster vaccine (if received) was BNT162b2 vaccine 133 134 (Pfizer-BioNTech). Participants with other vaccine combinations were excluded 135 because of the small numbers involved.

136

137 **Primary Outcome**

The primary outcome was a PCR-confirmed SARS-CoV-2 infection, irrespective of the participant's symptom status. This outcome was defined as a primary infection in the previously uninfected cohort or a reinfection in the previously infected cohort (two PCR-positive samples \geq 90 days apart or, if the primary infection PCR is not available, a new PCR-positive sample \geq 28 days after an antibody-positive result consistent with previous infection).

Participants could move from the previously uninfected cohort to the previously infected cohort 90 days after their PCR-positive test. For individual participants, the end of follow-up was the date of primary infection (in the previously uninfected cohort), the date of reinfection (in the previously infected cohort), or the date of the last PCR-negative test.

149

150 Statistical Analysis

151 In our Cox proportional-hazards model, the outcome was time to PCR-positive SARS-CoV-2 infection, and main predictors — vaccination status and previous 152 153 infection status — were categorical and time-varying. We stratified according to age 154 group, geographic region, and frequency of exposure to persons with Covid-19. We 155 chose stratification based on these categorical predictors because they were 156 statistically significant when controlled for but did not satisfy the proportional-hazards 157 assumption (Schoenfeld test, according to predictor and global fit). We also 158 controlled for sex, ethnic group and workplace setting (see Supplementary tables A.1 159 through A.6), because we observed that these predictors were statistically 160 significant, led to a significant increase in the likelihood value (likelihood ratio test) 161 and satisfied the proportional-hazards assumptions In Tables 1-3, we also report estimates from an unadjusted model, without stratifying or controlling for any 162 163 predictor other than the time since vaccination and infection. The model accounted 164 for calendar time, which is crucial given the varying infection rate, through the 165 baseline hazard that can take any functional form. In this model, the hazard is 166 assumed to be

$$h_{i}(t) = h_{0i}(t) \exp(\beta_1 x_1 + \dots + \beta_k x_k)$$

with a time-varying baseline hazard $h_{0i}(t)$ for each stratum. We estimated the parameter β , report the hazard ratio HR=exp(β), and report vaccine effectiveness and protection from primary infection calculated as 1 minus the hazard ratio, along with Wald statistic confidence intervals. The estimates of the hazard ratios are independent of the baseline hazard, on which no assumption was made.

173 We conducted analyses separately for the periods of Delta-variant and Omicronvariant dominance, splitting follow-up time: Delta 07/09/2021 to 30/11/2021; Omicron 174 175 13/12/2021 to 28/02/2022. We defined three post-V3 time intervals for the Omicron period: 0 - 2 months, 2 - 4 months (upper bound included) and >4 months. For the 176 177 Delta period we have a single interval approximately corresponding to the first two months after the third dose, before Omicron's dominance. The baseline was either 178 179 8+ months after a second dose of BNT162b2, or, alternatively, 6+ months after a 180 second dose of ChAdOx1. We first fitted the model in the previously uninfected 181 cohort with vaccination status as a predictor with postvaccination (post-booster) 182 intervals further categorized according to manufacturer of the vaccine administered 183 in the primary course. The VE estimates represent the additional protection associated with a booster, relative to a waned primary course 184

185 We then performed analyses on both previously uninfected and previously infected 186 participants, introducing previous infection status. First, we estimated the protection associated with primary infection. We grouped previous infection status into 6 187 188 categories: no primary infection, 3-6 months, 6<9, 9<12, 12-15 and >15 months after 189 primary infection. We fitted a model where time since primary infection and time since vaccination are added as marginal predictors, without interactions. For the 190 191 Delta period, we considered additional vaccine status categories (see table 2) in 192 order to have enough follow-up time to obtain estimates. With this model we 193 estimate protection associated with a previous infection, assuming that it is 194 independent from vaccine status. In order to test this assumption, we fitted a model 195 with interaction between the two predictors and verified that interaction terms were 196 not significant. For this interaction model we split time since primary infection in only 197 two categories, 3-12 and more than 12 months ago, to ensure convergence of 198 hazard ratios on all combinations. We assumed that if interactions were not 199 significant on a coarse scale, they would not appear in a more granular one. In Table 2 we only report the estimates for the previous infection categories, but not for
 vaccine status (see supplementary tables A.3 and A.4 for all estimates)

202 Next, we focussed on protection associated with third-dose vaccination and previous 203 infection (hybrid immunity). We selected the recipients of the BNT162b2 vaccine and 204 fitted a model with combination of the time since the primary infection (3-12 and 205 more than 12 months ago) and the time since vaccination (table 3). The baseline 206 here was a waned primary course of vaccination without any previous infection. The 207 VE estimates from this model represent the combined effect associated with booster 208 and previous infection. Recipients of the ChAdOx1 nCoV-19 vaccine for their primary 209 course were excluded because of small numbers in the previously infected cohort.

Goodness of fit was assessed with the use of the likelihood ratio test (against the null model) and Akaike information values. The widths of the confidence intervals have not been adjusted for multiplicity and cannot be used to infer effects. We used robust variance estimates to guard against the potential for unmeasured confounders at the study site level.

215 We performed sensitivity analyses to assess the extent of depletion-of-susceptibles 216 and the effect of excluding participants who enrolled in the extension for the Delta 217 period, or that did not enrol for the Omicron period. All the sensitivity analyses 218 provided results that were similar to those presented here, but the estimates were 219 more uncertain (see Tables B.1 through C.6). All the analyses were conducted with the use of Stata software, version 15.1 (StataCorp). The results were independently 220 221 replicated with the use of R software, version 4.1.1, survival package v.3.2-13 (R 222 Foundation for Statistical Computing). Our annotated code is available at 223 https://github.com/SIREN-study/SARS-CoV-2-Immunity.

224

225 **RESULTS**

226 Study population

We included a total of 19,614 individuals who were participating in regular SIREN testing between September 2021 and February 2022. The cohort were predominantly female (84%), of white ethnicity (89%), with a median age of 47 (IQR 16), 74% reported no comorbidities, and 69% were employed in clinical roles(Supplementary Table i).

232 We analysed protection over two different time periods: Delta (07 September 2021 to 30 November 2021; n= 18,429) and Omicron (13 December 2021 to 28 February 233 234 2022; n= 16,458) (Table 1). Third-dose vaccinations were introduced into our cohort 235 on 16 September 2021 and coverage was 95% by the end of the analysis period 236 (Supplementary Figure 1). On 15 September 2021, 29% had a history of SARS-CoV-237 2 infection, of which 1,901 (65%) were presumed infected in the Wild-Type period, 238 688 (24%) in the Alpha variant period and 8 (0.3%) in the Delta variant period (prior 239 to the start of this analysis).

In the previously uninfected cohort, the PCR testing frequency before and after V3 was every 15.7 days and 11.2 days respectively in the Delta period and 11.0 days and 8.6 days in the Omicron period. In the previously infected cohort, in the Delta period it was every 14.2 and 11.7 days before and after V3; in the Omicron period it was 11.3 and 8.9 days.

245 **Primary outcome**

There were 2467 primary infections and 881 reinfections during the Omicron period, primary infections and 85 reinfections during the Delta period. Cumulative incidence rates were higher against Omicron (primary: 43/10,000 person-days, reinfections: 32/10,000 person-days) than Delta (primary: 4/10,000 person-days, reinfections: 1/10,000 person-days).

Relative vaccine effectiveness following third dose in previously uninfected participants

In the previously uninfected cohort, third doses increased protection against both variants relative to waned dose-2 but were less effective against Omicron (Vaccine Effectiveness (VE) 0-2 months post-V3, 3-doses BNT162b2: 35% (95% Confidence Interval (CI) 21%-47%) vs. 63% (CI 40%-77%) than Delta (table 1). Heterologous third doses (BNT162b2, 2-dose ChAdOX1) were especially effective; with VE 0-2 months post-V3 over \geq 68% for both variants. Dose-3 protection waned rapidly against Omicron, with no additional benefit >4-months.

260 **Protection from previous infection**

When included as a marginal predictor, previous infection continued to provide additional protection against Omicron (67% (CI 56%-75%) 3-6 months postinfection), but this waned after 9 months to around 25%, markedly lower than against Delta where it remained at 85% (CI 81% - 89%) after more than 15 months (table 2). We found no evidence of interaction between vaccine-acquired and infectionacquired protection.

267 Relative protection following infection and vaccination (hybrid protection)

268 In the previously infected cohort, with participants with two waned BNT162b2 doses 269 and no previous infections as the reference group, we saw additional benefit 270 associated with previous infection (table 3). Against Delta, a third dose and previous 271 infection were associated with around 90% additional protection, even more than 272 one year after primary infection. Against Delta, the combined additional protection 273 remained around 70% for previous infection less than one year ago and around 50% 274 for previous infection more than one year ago. Despite wide confidence intervals in 275 the 4-month post-V3 category (reflecting small numbers of participants), there is an 276 indication that the additional protective effect associated with previous infection 277 wanes over time against Omicron, as in Table 2.

278

279 **DISCUSSION**

280 In the wake of surging infections in the SIREN cohort driven by the Omicron-variant, 281 deployment of third doses of BNT162b2 vaccines provided short-term protection 282 against infection but this waned rapidly. Vaccinated and previously infected 283 participants continued to have higher protection than those without previous 284 infection, but this reduced with time since infection in the Omicron period. Protection 285 in the Omicron period contrasted sharply with that of the Delta period, from both 286 vaccines and previous infection, with both providing more modest impact against 287 Omicron infections.

288 Short-term increased protection following vaccine third doses against Omicron 289 infections, including symptomatic infections and severe illness, has been observed in 290 other studies^{5,17-19}. Others have also reported reduced vaccine effectiveness against 291 Omicron compared to Delta, and rapid waning.^{7,8,18,20,21} Our finding of more pronounced benefit following third doses among ChAdOX1 primary course recipients
 who received a heterologous third dose (BNT162b2), has been observed in both
 trials and real-world studies, related to the lower effectiveness of the ChAdOX1
 primary series.^{10,18}

296 For previous strains of SARS-CoV-2, hybrid immunity offers greater and more 297 durable protection against reinfection than infection or vaccination alone, with protection remaining >90% more than a year after primary infection.⁶ In this current 298 analysis, this trend continued whilst the Delta-variant dominated, and then diverged 299 300 with the emergence of Omicron. Whilst during the Omicron period the previously 301 infected cohort maintained higher protection against (re)infection than the previously 302 uninfected cohort, the impact was reduced, and showed evidence of waning just nine 303 months after infection. Given the distinct SARS-CoV-2 variant waves experienced by our cohort,²² participants in the Omicron analysis who had been infected less than 304 305 nine months previously were most likely infected by Delta-variant, those infected 9-306 12 months ago had Alpha-variant infections, and those infected over 15 months ago 307 had Wild-type infections. Possible explanations for this lower protection afforded by 308 a primary infection sustained over 9 months ago could be greater antigenic distance 309 between successive variants, with a less effective neutralisation response to Omicron from a wildtype infection than a Delta infection, or antibody waning over 310 time.12,23-26 311

The continued additional protection from hybrid immunity compared to vaccine alone suggests that there are alternative immunological pathways which confer greater protection. Most notable are differences with neutralising antibody (nAb) titres and breadth of neutralisation with hybrid immunity compared to vaccine or infection induced immunity.²⁷⁻³³ There are other immunological differences between the groups, including in tissue-resident memory T-cells, and the mucosal immune system,³³⁻³⁶ which has prompted interest in development of intranasal vaccination.³⁷

319

The key strengths of our study include the size of our cohort undergoing frequent PCR testing independent of disease status, giving us confidence that most infections were detected. Having monitored our well-characterised cohort for infections and vaccination since June 2020, we have a valuable history of antigenic exposures for 324 all our participants, enabling analysis of time since infection. The speed of third-325 dose vaccine deployment and frequent testing, independent of symptoms, considerably limited the effect of the depletion-of-susceptibles bias (supplementary 326 appendix B). ³⁸ This is especially relevant for Omicron, which is more often 327 associated with less severe or asymptomatic disease,³⁹ therefore infections are more 328 likely to be missed, putting studies without frequent and asymptomatic testing at risk 329 330 from the bias.⁴⁰ In our cohort, frequency of testing during the Omicron period was high (every 8-9 days), therefore our estimates - and importantly the waning 331 332 highlighted - are unlikely to be affected. Given the early start of third-dose 333 deployment in our cohort, we were able to estimate the effectiveness of the third 334 dose in the Delta dominant period in addition to the Omicron period, and the 335 contrasting results powerfully demonstrate the step-change introduced by the 336 Omicron-variant. The unspecified and varying baseline hazard rate of the Cox 337 model is crucial to obtain reliable estimates in a period like winter 2021-2022, with a 338 rapidly evolving wave of infections and changing recommendations for social 339 distancing.

340

341 The most important limitation in our study is that we were unable to estimate 342 absolute vaccine effectiveness and protection as too few participants remained 343 unvaccinated to provide the reference group in this analysis. However, following the 344 success of COVID-19 vaccine campaigns in high-income countries, this challenge is 345 not unique to SIREN, and moreover, our selection of waned dose-2 participants as 346 our reference group was appropriate given the decision to deploy third doses was in 347 response to evidence of primary course vaccine waning. A further limitation is that 348 testing tended to be less frequent before V3 than after; this might have led to 349 underestimating V3 effectiveness.

Mass deployment of BNT162b2 vaccine third doses in response to the Omicron surge provided short-term protection against infection, and therefore helped mitigate record levels of SARS-CoV-2 infections in the UK. The rapid subsequent waning of vaccine protection is a significant challenge for future sustainable control measures, and future COVID-19 vaccine policy. Hybrid-immunity is increasingly commonplace. Our findings of reduced protection from hybrid-immunity in the Omicron era

- 356 demonstrate the complexity of an evolving pandemic with potential emergence of
- immune-escape variants. This underscores the importance of continued longitudinal
- 358 studies with well-characterised cohorts and reliable antigenic history.
- 359

360 Data sharing

- 361 The metadata will be available through the Health Data Research UK Co-Connect platform.
- 362 Anonymised data will be made available for secondary analysis to trusted researchers upon
- 363 reasonable request.

364 Declaration of interests

365 We declare no competing interests.

366 Funding statement

- 367 The SIREN study is funded by UK Health Security Agency and the Department of Health,
- 368 with contributions from the Northern Irish, Scottish and Welsh governments. The study
- 369 receives support from the National Institute for Health Research (NIHR) as an Urgent Priority
- 370 Study. SH and VJH are supported by the NIHR Health Protection Research Unit in
- 371 Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in
- 372 partnership with UKHSA (NIHR200915). FI was supported by Imperial College's President's
- 373 PhD Scholarship. The study has received grant funding from the Medical Research Council
- 374 (Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK
- 375 healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway, MR/W02067X/1).

376 Statement of contributions

- VH, FI and SF are joint first authors. VH, FI, SF, AC and SH designed the analysis plan.
- 378 VH, FI and SF wrote the first draft. SF led on data management, cleaning and descriptive
- analysis. FI designed and undertook the statistical analysis, including sensitivity analyses,
- 380 with statistical oversight provided by AC. PK independently replicated the statistical analysis
- in an alternative programme (R). SF, FI, PK and VH had full access to and analysed the data
- 382 for this analysis. DS undertook and wrote the literature review. SF, AA, MC, JI, LP, DC, EL,
- 383 CSB, are responsible for study delivery, oversight and ongoing data collection. SH is the
- 384 Chief Investigator for the SIREN study and VH is the study lead, and guarantors of the study.
- 385 All authors reviewed the draft manuscript and approved the final version for submission. All
- authors had full access to all the data in the study and accept responsibility to submit for
- 387 publication.

388 **REFERENCES**

389 JCVI. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 1. 390 2022. https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-391 booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-392 vaccine-programme-for-winter-2021-to-2022#fn:1, 2021. 393 2. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease 394 by Covid-19 Vaccines. N Engl J Med 2022; 386(4): 340-50. 395 Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against 3. 396 SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun 2022; 13(1): 3082. 397 Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA 4. 398 vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: 399 prospective observational study. BMJ 2022; 376: e069761. 400 Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant 5. 401 from Previous SARS-CoV-2 Infection. New England Journal of Medicine 2022; 386(13): 1288-90. 402 Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination 6. 403 and Previous Infection. N Engl J Med 2022; 386(13): 1207-20. 404 Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive 7. 405 for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Intern Med 406 2022; 182(2): 179-84. 407 8. Šmíd M, Berec L, Přibylová L, et al. Protection by Vaccines and Previous Infection Against the 408 Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious 409 Diseases 2022. 410 9. Zeng C, Evans JP, Qu P, et al. Neutralization and Stability of SARS-CoV-2 Omicron Variant. 411 bioRxiv 2021. 412 10. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 413 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK 414 (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021; 415 **398**(10318): 2258-76. 416 Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters 11. 417 induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2022; 185(3): 457-66 e4. 418 12. Perez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 419 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. 420 Nat Med 2022; 28(3): 481-5. 421 13. JCVI. JCVI advice on the UK vaccine response to the Omicron variant. 422 https://www.gov.uk/government/publications/uk-vaccine-response-to-the-omicron-variant-jcvi-423 advice/jcvi-advice-on-the-uk-vaccine-response-to-the-omicron-variant, 2021. 424 14. Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-425 EM structure of spike protein-ACE2 complex. Science 2022; 375(6582): 760-4. 426 15. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing 427 antibodies. Nature 2022; 602(7898): 657-63. Wallace S, Hall V, Charlett A, et al. Impact of prior SARS-CoV-2 infection and COVID-19 428 16. 429 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study 430 among UK healthcare workers - the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study 431 protocol. BMJ Open 2022; 12(6): e054336. 432 Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-17. 433 19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA 434 2022; **327**(7): 639-51. 435 Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron 18.

436 (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.

437 19. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA 438 COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021; 439 **398**(10316): 2093-100. 440 20. Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 441 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-442 1273 vaccination series: A Danish cohort study. medRxiv 2021: 2021.12.20.21267966. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against 443 21. 444 SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications 2022; 13(1): 3082. 445 Foulkes S, Monk EJM, Sparkes D, et al. Early Warning Surveillance for SARS-CoV-2 Omicron 22. 446 Variants, United Kingdom, November 2021-September 2022. Emerg Infect Dis 2023; 29(1): 184-8. 23. 447 Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 448 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med 2022; 449 14(637): eabn8057. 450 24. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 2021; 397(10292): 2331-3. 451 Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer 452 25. 453 BNT162b2 neutralization. Nature 2022; 602(7898): 654-6. 454 Epsi NJ, Richard SA, Lindholm DA, et al. Understanding 'hybrid immunity': comparison and 26. 455 predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines. Clin Infect 456 Dis 2022. 457 Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth 27. 458 to SARS-CoV-2 variants. Sci Immunol 2022: eabp8328. 459 Martinek J, Tomaskova H, Janosek J, et al. Immune Response 5-7 Months after Vaccination 28. 460 against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three 461 Vaccines. Viruses 2022; 14(5). 462 Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. 29. 463 Immunol Rev 2022; **310**(1): 27-46. 464 30. Crotty S. Hybrid immunity. *Science* 2021; **372**(6549): 1392-3. 465 31. Walls AC, Sprouse KR, Bowen JE, et al. SARS-CoV-2 breakthrough infections elicit potent, 466 broad, and durable neutralizing antibody responses. Cell 2022; 185(5): 872-80 e3. 467 32. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads 468 to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol 2022; 469 7(68): eabn8014. 470 33. Angyal A, Longet S, Moore SC, et al. T-cell and antibody responses to first BNT162b2 vaccine 471 dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective 472 cohort study. Lancet Microbe 2022; 3(1): e21-e31. 473 Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response 34. to SARS-CoV-2. Sci Transl Med 2021; 13(577). 474 475 35. Rodda LB, Morawski PA, Pruner KB, et al. Imprinted SARS-CoV-2-specific memory 476 lymphocytes define hybrid immunity. Cell 2022; 185(9): 1588-601 e14. 477 36. Martinuzzi E, Benzaquen J, Guerin O, et al. A Single Dose of BNT162b2 mRNA Vaccine 478 Induces Airway Immunity in SARS-CoV-2 Naive and recovered COVID-19 subjects. Clin Infect Dis 479 2022. 480 37. Lei H, Alu A, Yang J, et al. Intranasal administration of a recombinant RBD vaccine induces 481 long-term immunity against Omicron-included SARS-CoV-2 variants. Signal Transduct Target Ther 482 2022; 7(1): 159. 483 38. Lipsitch M, Goldstein E, Ray GT, Fireman B. Depletion-of-susceptibles bias in influenza 484 vaccine waning studies: how to ensure robust results. Epidemiol Infect 2019; 147: e306. 485 39. Garrett N, Tapley A, Andriesen J, et al. High Rate of Asymptomatic Carriage Associated with 486 Variant Strain Omicron. medRxiv 2022.

487 40. Kahn R, Schrag SJ, Verani JR, Lipsitch M. Identifying and Alleviating Bias Due to Differential
488 Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. *Am J Epidemiol*489 2022; **191**(5): 800-11.

Table 1: Vaccine effectiveness in the previously uninfected cohort against Delta and Omicron infections, September 2021 – February 2022

Vaccine status	Number of participants	Number _ of days of follow up	All primary infections (symptomatic & asymptomatic)				
			Number of primary infections	Crude Incident rate (per 10,000)	VE (1-HR) 95% Cl	aVE (1-HR) 95% Cl	
DELTA					-		
Primary course BNT162b2							
Vaccine second dose more than eight months ago	1870	31680	29	9.15	ref	ref	
Vaccine third dose (BNT162b2 booster) 0-2 months	11232	500852	177	3.53	0.69 (0.52-0.8)	0.63 (0.4-0.77)	
Primary course ChAdOX1							
Vaccine second dose more than four months ago	483	9127	15	16.43	ref	ref	
Vaccine third dose (BNT162b2 booster) 0-2 months	540	18649	7	3.75	0.77 (0.28-0.92)	0.77 (0.37-0.91)	
OMICRON							
Primary course BNT162b2				-	-		
Vaccine second dose more than eight months ago	698	20416	151	73.96	ref	ref	
Vaccine third dose (BNT162b2 booster)							
0-2 months	4590	68350	249	36.43	0.43 (0.3-0.53)	0.35 (0.21-0.47)	
2-4 months	9179	389980	1627	41.72	0.46 (0.37-0.54)	0.34 (0.22-0.43)	
>4months	4093	54258	297	54.74	0.4 (0.24-0.53)	0.21 (0-0.38)	
Primary course ChAdOX1							
Vaccine second dose more than four months ago	143	3954	32	80.93	ref	ref	
Vaccine third dose (BNT162b2 booster)							
0-2 months	485	10596	28	26.43	0.66 (0.44-0.8)	0.68 (0.46-0.81)	
>2 months	484	20072	72	35.87	0.6 (0.39-0.73)	0.56 (0.32-0.72)	

Relative vaccine effectiveness in previously uninfected cohort. We have provided an estimate of relative protection, defining the reference group as participants previously uninfected who had received only two vaccines, and had received their second dose more than 8 months ago (BNT162b2 primary course) or more than 6 months ago (ChAdOX1 primary course). The unadjusted vaccine effectiveness model was adjusted for time since vaccination (and vaccine brand for primary course) and baseline hazard only. The adjusted vaccine effectiveness model was adjusted for time since vaccination (and vaccine brand for primary course), baseline hazard and constant predictors (sex, ethnic group, workplace setting) and stratified across age group, geographic region and frequency of exposure to patients with COVID-19. In the post-vaccination intervals, the upper time bound is included. Vaccine effectiveness was defined as 1 minus the hazard ratio. The hazard ratios associated with the additional predictors are given in Appendix A.

Vaccine status	Number of participants	Number of days . of follow up	All reinfections (symptomatic & asymptomatic)					
			Number of (re)infections	Crude Incident rate (per 10,000)	Protection (1-HR) 95% CI	Adjusted Protection (1-HR) 95% Cl		
DELTA	-	-	_	-	-	-		
No previous infection	19103	1935033	1125	5.81	Ref	ref		
Previous infection								
3-6 months	718	19590	1	0.51	0.90 (0.39-0.98)	0.90 (0.42-0.98)		
6-9 months	2006	89006	13	1.46	0.77 (0.61-0.86)	0.75 (0.59-0.85)		
9-12 months	2515	143138	34	2.38	0.61 (0.44-0.72)	0.63 (0.48-0.74)		
12-15 months	1953	59925	2	0.33	0.93 (0.71-0.98)	0.93 (0.72-0.98)		
More than 15 months	4595	398639	35	0.88	0.85 (0.81-0.89)	0.85 (0.81-0.89)		
OMICRON								
No previous infection	11074	569635	2467	43.31	ref	ref		
Previous infection								
3-6 months	784	30397	47	15.46	0.66 (0.55-0.74)	0.67 (0.56-0.75)		
6-9 months	243	5855	14	23.91	0.50 (0.11-0.72)	0.53 (0.2-0.73)		
9-12 months	970	23871	80	33.51	0.19 (-0.07-0.38)	0.27 (0.04-0.44)		
12-15 months	1660	61798	214	34.63	0.22 (0.1-0.33)	0.27 (0.16-0.37)		
More than 15 months	3099	150276	526	35.00	0.20 (0.1-0.29)	0.26 (0.17-0.34)		

Table 2: Protection from infection over time, controlled for vaccine status, during Delta-variant and Omicron-variant periods

Protection from reinfection associated with a primary infection (PI). We have controlled for vaccine status without interaction terms between previous infection and vaccine status, after having verified that interaction terms are not significant (Wald tests: p = 0.71 for Delta period, p = 0.67 for Omicron period). The adjusted model includes additional predictors (gender, ethnic group, workplace setting) and is stratified across age group, geographic region and frequency of exposure to patients with COVID-19. In the post-infection intervals, the upper time bound is included. Protection is defined as 1 minus the hazard ratio. The hazard ratios associated with the additional predictors and the interaction models are given in Appendix A.

Table 3: Protection from infection and booster vaccination (hybrid protection) during Delta-variant and Omicron-variant periods

	Number of participants	Number of days of follow up	All reinfections (symptomatic & asymptomatic)			
Vaccine status			Number of reinfections	Crude Incident rate (per 10,000)	VE (1-HR) 95% Cl	aVE (1-HR) 95% CI
DELTA						
Vaccine two doses more than eight months ago and no previous infection	1870	31680	29	9.15	ref	ref
Vaccine three doses and infection less than one year ago – 0-2 months	1715	55523	4	0.72	0.94 (0.81-0.98)	0.88 (0.66-0.96)
Vaccine three doses and infection more than one year ago – 0-2 months	2760	16249	2	1.23	0.94 (0.88-0.97)	0.9 (0.76-0.96)
OMICRON						
Vaccine two doses more than eight months ago and no previous infection	698	20416	151	73.96	ref	ref
Vaccine three doses and infection less than one year ago					-	
0-2 months	901	14825	31	20.91	0.7 (0.56-0.79)	0.66 (0.49-0.78)
2-4 months	1080	31993	70	21.88	0.72 (0.63-0.79)	0.68 (0.57-0.76)
>4 months	232	2698	6	22.24	0.76 (0.43-0.9)	0.77 (0.33-0.92)
Vaccine three doses and infection more than one year ago					-	
0-2 months	1909	34166	94	27.51	0.6 (0.48-0.69)	0.57 (0.45-0.66)
2-4 months	3273	128921	457	35.45	0.54 (0.45-0.62)	0.48 (0.38-0.57)
>4 months	1313	16579	69	41.62	0.53 (0.37-0.66)	0.41 (0.17-0.58)

Protection from infection and booster vaccination (hybrid protection) during Delta-variant and Omicron-variant periods, in BNT162b2 recipients. We have provided an estimate of hybrid protection relative to a waned primary course, defining the reference group as participants previously uninfected who had received only two Pfizer vaccines, with second dose more than 8 months ago. In the post-vaccination intervals, the upper time bound is included. Protection is defined as 1 minus the hazard ratio. The adjusted vaccine effectiveness (aVE) model includes additional predictors (gender, ethnic group, workplace setting) and is stratified across age group, geographic region and frequency of exposure to patients with COVID-19. The hazard ratios associated with the additional predictors are given in Appendix A.

FIGURES

Figure 1a: Relative vaccine effectiveness following BNT162b2 V3 after BNT162b2 primary course by time since vaccination, against Delta-variant and Omicron-variant infections, among previously unifected cohort



Footnote: The estimates refer to VE relative to waned dose 2 (>8 months post second dose)

Figure 1b: Relative vaccine effectiveness following BNT162b2 V3 after ChAdOX1 primary course by time since vaccination, against Delta-variant and Omicron-variant infections, among previously unifected cohort



Footnote: The estimates refer to VE relative to waned dose 2 (>6 months after second dose).

Figure 2:

Protection from infection over time, controlled for vaccine status, during Delta-variant and Omicron-variant periods



Protection from previous infection

Figure 3:

Protection from infection and BNT162b2 third-vaccine dose (hybrid protection) during Delta-variant and Omicron-variant periods



Hybrid protection in positive cohort

Footnote: The estimates refer to VE relative to waned dose 2 (>8 months before) of a BNT162b2 Primary course with no previous infection.